Last reviewed 2026-04-19 · How we verify

[F-18]AV-1451

David Okonkwo, MD, PhD · Phase 2 active Small molecule

[F-18]AV-1451 is a Small molecule drug developed by David Okonkwo, MD, PhD. It is currently in Phase 2 development. Also known as: [F-18]T807, LY3191748.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	[F-18]AV-1451
Also known as	[F-18]T807, LY3191748
Sponsor	David Okonkwo, MD, PhD
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[F-18]AV-1451 CI brief — competitive landscape report
[F-18]AV-1451 updates RSS · CI watch RSS
David Okonkwo, MD, PhD portfolio CI

Frequently asked questions about [F-18]AV-1451

What is [F-18]AV-1451?

[F-18]AV-1451 is a Small molecule drug developed by David Okonkwo, MD, PhD.

Who makes [F-18]AV-1451?

[F-18]AV-1451 is developed by David Okonkwo, MD, PhD (see full David Okonkwo, MD, PhD pipeline at /company/david-okonkwo-md-phd).

Is [F-18]AV-1451 also known as anything else?

[F-18]AV-1451 is also known as [F-18]T807, LY3191748.

What development phase is [F-18]AV-1451 in?

[F-18]AV-1451 is in Phase 2.

Manufacturer: David Okonkwo, MD, PhD — full pipeline
Also known as: [F-18]T807, LY3191748

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing